Cancer related anaemia (CRA)
An overview of approach and treatment
Keywords:
CRA, management, iron supplements, erythropoietin-stimulating agentsAbstract
Cancer-related anemia (CRA) is a complicated and multifaceted problem that can occur as a result of tumor, as an adverse reaction of chemotherapeutic agent, or as a result of neurotoxic effects. The symptoms of CRA vary depending on an individual's response to blood loss or reduction in the number of red blood cell production. Patients with severe anemia have different characteristics depending on the type of haematological malignancy they have. Clinical and biochemical evaluations, as well as bone marrow examinations, may be useful diagnostic tools in many cases. Iron therapy can be usedalone or in combination with ESA to improve the response of Hb and to decrease the need of RBC transfusion. lood transfusion carries a number of risks, some of which can be mitigated or even eliminated.. Even though erythropoietin-stimulating agents (ESAs) have been shown to be effective in preventing anemia and reducing the need for blood transfusions, it would be helpful for identifying high-risk patient groups that would benefit the most from these expensive treatments. Blood transfusions should be used on a specific instance basic principle in patients with advanced cancer, depending on the extent of distressing symptoms and life expectancy.
Downloads
References
Cheng K, Zhao F, Gao F, Dong H, Men H-T, Chen Y, et al (2012). Factors Potentially Associated with Chemotherapy-induced Anaemia in Patients with Solid Cancers. Asian Pacific Journal of Cancer Prevention; 13 (10):5057-5061.
Wan S, Lai Y, Myers RE, Li B, Palazzo JP, Burkart AL, et al (2013). Post-diagnosis haemoglobin change associates with overall survival of multiple malignancies – results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers. BMC Cancer; 13:341-351
World Health Organization. Cancer. 2017. http://www.who.int/mediacentre/factsheets/fs297/en/. Assessed 25 Apr 2017.
Pourali L, Taghizadeh A, Akhoundi M R, Varshoei F, Zarifian A, et al (2017). Frequency of Chemotherapy Induced Anaemia in Breast Cancer Patients, Intonational Journal of Cancer Management.; 10(1):e4672.
Madeddu, C., Gramignano, G., Astara, G., Demontis, R., Sanna, E., Atzeni, V., et al. (2018). Pathogenesis and Treatment Options of Cancer Related Anaemia: Perspective for a Targeted Mechanism-Based Approach. Frontiers in physiology, 9, 1294.
Fares Mohammed Saeed Muthanna, Bassam Abdul Rasool Hassan, Mahmathi Karuppannan, Ali Haider Mohammed, Evaluation of the impact of anaemia on quality of life among breast cancer patients undergoing chemotherapy in Malaysia. Journal of Pharmaceutical Health Services Research, Volume 12, Issue 2, June 2021, Pages 310–312, https://doi.org/10.1093/jphsr/rmaa033
Maccio, A.; Madeddu, C.; Gramignano, G.; Mulas, C.; Tanca, L.; Cherchi, M.C.; et al. (2015) . The role of inflammation, iron, and nutritional status in cancer-related anaemia : Results of a large, prospective, observational study. Haematologica, 100, 124–132.
Macciò, A., Madeddu, C., Gramignano, G., Mulas, C., Tanca, L., Cherchi, M. C., et al. (2015). The role of inflammation, iron, and nutritional status in cancer-related anaemia: results of a large, prospective, observational study. Haematologica, 100(1), 124–132.
Muthanna, Fares Mohammed Saeed, Mahmathi Karuppannan, Bassam Abdul Rasool Hassan, and Ali Haider Mohammed. (2021). "Impact of fatigue on quality of life among breast cancer patients receiving chemotherapy." Osong Public Health and Research Perspectives 12, no. 2 : 115.
Knight K, Wade S, Balducci L. (2004). Prevalence and outcomes of anaemia in cancer: A systematic review of the literature. Am J Med; 116: 11– 26.
Muthanna, Fares MS, Mahmathi Karuppannan, Bassam Abdul Rasool Hassan, and Ali Haider Mohammed. "Assessment of Risk Factors Associated with Anaemia Severity among Breast Cancer Patients Undergoing Chemotherapy in Malaysia." Systematic Reviews in Pharmacy 11, no. 12 (2020): 2405-2411.
Steegmann JL, Torres JMS , Colomer R, Vaz A , Lo´pez J , Jalo´n I, et al (2013). Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. ClinTranslOncol; 15:477–483
Busti, F., Marchi, G., Ugolini, S., Castagna, A., & Girelli, D. (2018). Anaemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. Pharmaceuticals (Basel, Switzerland), 11(4), 94.
Dicato M, Plawny L, Diederich M ( 2010) . Anaemia in cancer .Annals of Oncology ;21: 167–172
Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascón, P., & ESMO Guidelines Committee et al. (2018). Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of oncology: official journal of the European Society for Medical Oncology, 29(Suppl 4), iv96–iv110
Bohlius, J., Bohlke, K., Castelli, R., Djulbegovic, B., Lustberg, M. B., Martino, M., et al. (2019). Management of Cancer-Associated Anaemia with 202 Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 37(15), 1336–1351.
Choon, S., Chan, L., Choon, S. E., et al.. (2014). Malaysian Clinical Practice Guideline for the Management of Psoriasis Vulgaris: Summary of recommendations for management in primary healthcare setting. Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia, 9(1), 16–21.
Rodgers, G.M.; Gilreath, J.A. (2019). The Role of Intravenous Iron in the Treatment of Anaemia Associated with Cancer and Chemo-therapy. Acta Haematol. 142, 13–20.
Grogan, M.; Thomas, G.M.; Melamed, I.; Wong, F.L.; Pearcey, R.G.; Joseph, P.K.; Portelance, L.; Crook, J.; Jones, K.D (1999). The impor- tance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer, 86, 1528–1536.
Mercadante, S.; Ferrera, P.; Villari, P.; David, F.; Giarratano, A.; Riina, S. (2009). Effects of red blood cell transfusion on anaemia -related symptoms in patients with cancer. J. Palliat. Med., 12, 60–63.
Brown, E.; Hurlow, A.; Rahman, A.; Closs, S.J.; Bennett, M.I. (2010). Assessment of fatigue after blood transfusion in palliative care patients: A feasibility study. J. Palliat. Med, 13, 1327–1330
Goodnough, L.T (2005). Risks of blood transfusion. Anesthesiol. Clin. North. Am., 23, 241–252.
Khorana, A.A.; Francis, C.W.; Blumberg, N.; Culakova, E.; Refaai, M.A.; Lyman, G.H. (2008). Blood transfusions, thrombosis, and mortal- ity in hospitalized patients with cancer. Arch. Intern. Med, 168, 2377–2381.
Storring, P.L.; Tiplady, R.J.; Gaines Das, R.E.; Stenning, B.E.; Lamikanra, A.; Rafferty, B.; Lee, J. (1998). Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br. J. Haematol. 100, 79–89.
Tonia, T.; Mettler, A.; Robert, N.; Schwarzer, G.; Seidenfeld, J.; Weingart, O.; Hyde, C.; Engert, A.; Bohlius, J. (2012). Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst. Rev., 12, Cd003407
Smith, R.E., Jr.; Aapro, M.S.; Ludwig, H.; Pintér, T.; Smakal, M.; Ciuleanu, T.E.; Chen, L.; Lillie, T.; Glaspy, J.A. (2008). Darbepoetin alpha for the treatment of anaemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Oncol. 26, 1040–1050
Nekoui, A.; Blaise, G. Erythropoietin and Nonhematopoietic Effects. Am. J. Med. Sci. 2017, 353, 76–81.
Rodgers, G. M., Becker, P. S., Blinder, M., Cella, D., Chanan-Khan, A., Cleeland, C., Coccia, P. F., et al. (2012). Cancer- and chemotherapy-induced anaemia. Journal of the National Comprehensive Cancer Network: JNCCN, 10(5), 628–653.
Toblli, J.E.; Angerosa, M. (2014). Optimizing iron delivery in the management of anaemia : Patient considerations and the role of ferric carboxymaltose. Drug Des. Dev. Ther. 8, 2475–2491.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
